Condition 1: ventilator associated pneumonia. Condition 2: ventilator associated pneumonia. Condition 3: ventilator associated pneumonia. Condition 4: ventilator associated pneumonia. Condition 5: ventilator associated pneumonia. Condition 6: ventilator associated pneumonia. Pneumonia due to Streptococcus pneumoniae Pneumonia due to other infectious organisms, not elsewhere classified Pneumonia due to Haemophilus influenzae Bacterial pneumonia, not elsewhere classified Pneumonia in diseases
Conditions
Interventions
Intervention 1: Intramuscular injection of 300,000 IU of vitamin D in the treatment group as a single dose on the first day of treatment only. Intervention 2: Intramuscular injection of vitamin D plac
Treatment - Drugs
Intramuscular injection of 300,000 IU of vitamin D in the treatment group as a single dose on the first day of treatment only
Intramuscular injection of vitamin D placebo in the control group as a single dose on the first day of study
Sponsors
Chancellor for research, shahid beheshti medical university
Eligibility
Sex/Gender
All
Age
17 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients over 18 years old, that clinically and based on the following criteria have been diagnosed with VAP (During the first 48 hours of diagnosis): The presence of new or progressive infiltration on the patient's chest radiograph that occur 48-72 hours after initiation of mechanical ventilation, While two of the following symptoms must be present with it: Fever over 38 ° C; leukocytosis or leukopenia (white blood cell count greater than 12,000 per µL of blood or less than 4000 per µL blood) and purulent pulmonary secretions. Exclusion criteria: Stage3 or more chronic kidney problems; liver problems with CHILD-PUGH stage B or C; history of cancer within the last 3 months, or currently taking chemotherapy drugs; patients with immune deficiency; pancreatitis; other infections, concurrently with pneumonia caused by mechanical ventilation, patients with VAP that the vitamin D levels are normal and Coagulopathy.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Procalcitonin plasma level. Timepoint: Day 1 and 7 of study. Method of measurement: Plasma level that measured with electrochemiluminescence and reported as ng/ml.;C-reactive protein plasma level. Timepoint: Day 1 and 7 of study. Method of measurement: Plasma level that measured with elisa kit and reported as mg/L.;Interleukin-6 plasma level. Timepoint: Day 1 and 7 of study. Method of measurement: Plasma level that measured with elisa kit and reported as pg/ml.;Vitamin D plasma level. Timepoint: Day 1 and 7 of study. Method of measurement: Plasma level that measured with elisa kit and reported as ng/ml. | — |
Secondary
| Measure | Time frame |
|---|---|
| Outcom at 28 days. Timepoint: Day 28. Method of measurement: Evaluation of mortality. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contact"Salamzadeh Jamshi"
Shahid Beheshti University of Medical Sciences, School of Pharmacy
Outcome results
None listed